Drug Profile
Research programme: respiratory disorders therapeutics - Aradigm/CyDex
Alternative Names: ARD 1700Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Aradigm Corporation; CyDex
- Developer Aradigm Corporation; CyDex Pharmaceuticals
- Class Cyclodextrins
- Mechanism of Action Beta 2 adrenergic receptor agonists; Cholinergic receptor antagonists; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in USA (Inhalation)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (Inhalation)
- 26 Jan 2011 CyDex Pharmaceuticals has been acquired by Ligand Pharmaceuticals